Renal Cell Carcinoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. - UroToday



Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. 
UroToday
Renal cell carcinoma (RCC) consists of prognostic distinct subtypes derived from different cells of origin (eg, clear cell RCC [ccRCC], papillary RCC [papRCC], and chromophobe RCC [chRCC]). ccRCC is characterized by lipid accumulation and metabolic ...

 


Eosinophilic Solid and Cystic Renal Cell Carcinoma: An Emerging Renal Entity with Distinct Features - Beyond the ... - UroToday



Eosinophilic Solid and Cystic Renal Cell Carcinoma: An Emerging Renal Entity with Distinct Features - Beyond the ... 
UroToday
Figure 1: A) Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) shows solid and cystic appearance at low power. B) The septae between the cysts vary in thickness and are composed of eosinophilic (pink) cells, with voluminous cytoplasm; the ...

 


Atypical metastasis of renal cell carcinoma to the uvula: case report and review of literature - Dove Medical Press



Atypical metastasis of renal cell carcinoma to the uvula: case report and review of literature 
Dove Medical Press
Abstract: Renal cell carcinoma (RCC) is a common malignancy with high metastatic potential, primarily due to its extensive vascularity. Common sites of metastasis include lungs, bone, lymph nodes, liver, and brain. However, rare cases of metastasis to ...

 


AVEO Pharmaceuticals: Bright Prospects And Near-Term Catalysts In Renal Cell Carcinoma - Seeking Alpha



AVEO Pharmaceuticals: Bright Prospects And Near-Term Catalysts In Renal Cell Carcinoma 
Seeking Alpha
Sorafenib in first line Renal Cell Carcinoma (RCC) which precluded any meaningful comparison of overall survival (OS). With this FDA rejection the stock was rightly hammered and investor sentiment considerably damaged. But where disaster strikes ...

 


Relay For Life announces Honorary Chairs - River Falls Journal



River Falls Journal
 
Relay For Life announces Honorary Chairs 
River Falls Journal
That day I found out I had clear cell-renal cell carcinoma, kidney cancer. That was the bad news. The good news - it looked like it was contained to my right kidney. Kidney cancer is another silent, but slow growing cancer that can go undetected until ...

and more » 


PFS Improvement With Atezolizumab Combination in Metastatic Renal Cell Carcinoma - Targeted Oncology



Targeted Oncology
 
PFS Improvement With Atezolizumab Combination in Metastatic Renal Cell Carcinoma 
Targeted Oncology
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). J Clin Oncol. 2018;36 (suppl 6S; abstr 578). Allen E, Jabouille A, Rivera LB, et al. Combined antiangiogenic ...

 


First-line Pazopanib May Improve Outcomes in Advanced RCC - Renal and Urology News



Renal and Urology News
 
First-line Pazopanib May Improve Outcomes in Advanced RCC 
Renal and Urology News
SAN FRANCISCO?Progression-free survival (PFS) among patients with intermediate-risk advanced clear-cell renal cell carcinoma (aCCRCC) is significantly longer with pazopanib than temsirolimus as first-line therapy, according to the findings of a ...

 


ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma - UroToday



ASCO GU 2018: The Future of Immuno-Oncology in Renal Cell Carcinoma 
UroToday
Published 12 February 2018; San Francisco, CA (UroToday.com) Dr. Bernard Escudier provided one of the Keynote Lectures for kidney cancer at the GU ASCO 2018 meeting, discussing the future of immuno-oncology in renal cell carcinoma (RCC). The current ...

and more » 


Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma 
Oncology Nurse Advisor
Antibiotics may indirectly improve progression-free survival (PFS) among patients with metastatic renal cell carcinoma (RCC) receiving a first-line VEGF?tyrosine kinase inhibitor (TKI), according to research being presented at the 2018 Genitourinary ...
Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups Cancer Therapy Advisor

all 2 news articles » 


Papillary Renal Cell Carcinomas May Respond to Crizotinib - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Papillary Renal Cell Carcinomas May Respond to Crizotinib 
Cancer Therapy Advisor
Crizotinib may improve outcomes among patients with MET-positive papillary renal cell carcinoma type 1 (PRCC1), according to research being presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California.1. Patients with PRCC1 ...